Myeloablative chemotherapy for recurrent aggressive oligodendroglioma

Gregory Cairncross, Lode Swinnen, Robert Bayer, Steven Rosenfeld, Donna Salzman, Nina Paleologos, Lynn Kaminer, Peter Forsyth, Douglas Stewart, Kendra Peterson, Wendy Hu, David Macdonald, David Ramsay, Anne Smith

Research output: Contribution to journalArticle

Abstract

The objective of this study was to ascertain the duration of tumor control and the toxicities of dose-intense myeloablative chemotherapy for patients with recurrent oligodendrogliomas. Patients with previously irradiated oligodendrogliomas, either pure or mixed, that were contrast enhancing, measurable, and behaving aggressively at recurrence were eligible for this study. Only complete responders or major partial responders (75% reduction in tumor size) to induction chemotherapy - either intensive-dose procarbazine, lomustine, and vincristine or cisplatin plus etoposide - could receive high-dose thiotepa (300 mg/m2/day for 3 days) followed by hematopoietic reconstitution using either bone marrow or peripheral blood stem cells. Thirty-eight patients began induction chemotherapy and 20 (10 men, 10 women; median age 46 years; median Karnofsky score 80) received high-dose thiotepa. For the high-dose group, the median event-free, progression-free, and overall survival times from recurrence were 17, 20, and 49 months, respectively. Tumor control in excess of 2 years was observed in 6 patients (30%). Four patients (20%) are alive and tumor free 27 to 77 months (median, 42 months) from the start of induction therapy; however, fatal treatment-related toxicities also occurred in 4 patients (20%). Three patients died as a result of a progressive encephalopathy which, in 2 instances, was accompanied by a wasting syndrome; 1 patient died as a consequence of an intracerebral (intratumoral) hemorrhage. Fatal toxicities occurred in patients with pretreatment Karnofsky scores of 60 or 70. High-dose thiotepa to consolidate response was a disappointing treatment strategy for patients with recurrent aggressive oligodendroglial neoplasms, although several patients had durable responses. Moreover, as prescribed, high-dose thiotepa had significant toxic effects in previously irradiated patients, especially those with poorer performance status.

Original languageEnglish (US)
Pages (from-to)114-119
Number of pages6
JournalNeuro-Oncology
Volume2
Issue number2
StatePublished - Apr 2000
Externally publishedYes

Fingerprint

Oligodendroglioma
Drug Therapy
Thiotepa
Induction Chemotherapy
Neoplasms
Lomustine
Procarbazine
Wasting Syndrome
Recurrence
Poisons
Cerebral Hemorrhage
Brain Diseases
Vincristine
Etoposide
Cisplatin
Disease-Free Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Clinical Neurology
  • Oncology

Cite this

Cairncross, G., Swinnen, L., Bayer, R., Rosenfeld, S., Salzman, D., Paleologos, N., ... Smith, A. (2000). Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-Oncology, 2(2), 114-119.

Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. / Cairncross, Gregory; Swinnen, Lode; Bayer, Robert; Rosenfeld, Steven; Salzman, Donna; Paleologos, Nina; Kaminer, Lynn; Forsyth, Peter; Stewart, Douglas; Peterson, Kendra; Hu, Wendy; Macdonald, David; Ramsay, David; Smith, Anne.

In: Neuro-Oncology, Vol. 2, No. 2, 04.2000, p. 114-119.

Research output: Contribution to journalArticle

Cairncross, G, Swinnen, L, Bayer, R, Rosenfeld, S, Salzman, D, Paleologos, N, Kaminer, L, Forsyth, P, Stewart, D, Peterson, K, Hu, W, Macdonald, D, Ramsay, D & Smith, A 2000, 'Myeloablative chemotherapy for recurrent aggressive oligodendroglioma', Neuro-Oncology, vol. 2, no. 2, pp. 114-119.
Cairncross G, Swinnen L, Bayer R, Rosenfeld S, Salzman D, Paleologos N et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-Oncology. 2000 Apr;2(2):114-119.
Cairncross, Gregory ; Swinnen, Lode ; Bayer, Robert ; Rosenfeld, Steven ; Salzman, Donna ; Paleologos, Nina ; Kaminer, Lynn ; Forsyth, Peter ; Stewart, Douglas ; Peterson, Kendra ; Hu, Wendy ; Macdonald, David ; Ramsay, David ; Smith, Anne. / Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. In: Neuro-Oncology. 2000 ; Vol. 2, No. 2. pp. 114-119.
@article{08893870607d4fdaa1337f30076ffe7f,
title = "Myeloablative chemotherapy for recurrent aggressive oligodendroglioma",
abstract = "The objective of this study was to ascertain the duration of tumor control and the toxicities of dose-intense myeloablative chemotherapy for patients with recurrent oligodendrogliomas. Patients with previously irradiated oligodendrogliomas, either pure or mixed, that were contrast enhancing, measurable, and behaving aggressively at recurrence were eligible for this study. Only complete responders or major partial responders (75{\%} reduction in tumor size) to induction chemotherapy - either intensive-dose procarbazine, lomustine, and vincristine or cisplatin plus etoposide - could receive high-dose thiotepa (300 mg/m2/day for 3 days) followed by hematopoietic reconstitution using either bone marrow or peripheral blood stem cells. Thirty-eight patients began induction chemotherapy and 20 (10 men, 10 women; median age 46 years; median Karnofsky score 80) received high-dose thiotepa. For the high-dose group, the median event-free, progression-free, and overall survival times from recurrence were 17, 20, and 49 months, respectively. Tumor control in excess of 2 years was observed in 6 patients (30{\%}). Four patients (20{\%}) are alive and tumor free 27 to 77 months (median, 42 months) from the start of induction therapy; however, fatal treatment-related toxicities also occurred in 4 patients (20{\%}). Three patients died as a result of a progressive encephalopathy which, in 2 instances, was accompanied by a wasting syndrome; 1 patient died as a consequence of an intracerebral (intratumoral) hemorrhage. Fatal toxicities occurred in patients with pretreatment Karnofsky scores of 60 or 70. High-dose thiotepa to consolidate response was a disappointing treatment strategy for patients with recurrent aggressive oligodendroglial neoplasms, although several patients had durable responses. Moreover, as prescribed, high-dose thiotepa had significant toxic effects in previously irradiated patients, especially those with poorer performance status.",
author = "Gregory Cairncross and Lode Swinnen and Robert Bayer and Steven Rosenfeld and Donna Salzman and Nina Paleologos and Lynn Kaminer and Peter Forsyth and Douglas Stewart and Kendra Peterson and Wendy Hu and David Macdonald and David Ramsay and Anne Smith",
year = "2000",
month = "4",
language = "English (US)",
volume = "2",
pages = "114--119",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Myeloablative chemotherapy for recurrent aggressive oligodendroglioma

AU - Cairncross, Gregory

AU - Swinnen, Lode

AU - Bayer, Robert

AU - Rosenfeld, Steven

AU - Salzman, Donna

AU - Paleologos, Nina

AU - Kaminer, Lynn

AU - Forsyth, Peter

AU - Stewart, Douglas

AU - Peterson, Kendra

AU - Hu, Wendy

AU - Macdonald, David

AU - Ramsay, David

AU - Smith, Anne

PY - 2000/4

Y1 - 2000/4

N2 - The objective of this study was to ascertain the duration of tumor control and the toxicities of dose-intense myeloablative chemotherapy for patients with recurrent oligodendrogliomas. Patients with previously irradiated oligodendrogliomas, either pure or mixed, that were contrast enhancing, measurable, and behaving aggressively at recurrence were eligible for this study. Only complete responders or major partial responders (75% reduction in tumor size) to induction chemotherapy - either intensive-dose procarbazine, lomustine, and vincristine or cisplatin plus etoposide - could receive high-dose thiotepa (300 mg/m2/day for 3 days) followed by hematopoietic reconstitution using either bone marrow or peripheral blood stem cells. Thirty-eight patients began induction chemotherapy and 20 (10 men, 10 women; median age 46 years; median Karnofsky score 80) received high-dose thiotepa. For the high-dose group, the median event-free, progression-free, and overall survival times from recurrence were 17, 20, and 49 months, respectively. Tumor control in excess of 2 years was observed in 6 patients (30%). Four patients (20%) are alive and tumor free 27 to 77 months (median, 42 months) from the start of induction therapy; however, fatal treatment-related toxicities also occurred in 4 patients (20%). Three patients died as a result of a progressive encephalopathy which, in 2 instances, was accompanied by a wasting syndrome; 1 patient died as a consequence of an intracerebral (intratumoral) hemorrhage. Fatal toxicities occurred in patients with pretreatment Karnofsky scores of 60 or 70. High-dose thiotepa to consolidate response was a disappointing treatment strategy for patients with recurrent aggressive oligodendroglial neoplasms, although several patients had durable responses. Moreover, as prescribed, high-dose thiotepa had significant toxic effects in previously irradiated patients, especially those with poorer performance status.

AB - The objective of this study was to ascertain the duration of tumor control and the toxicities of dose-intense myeloablative chemotherapy for patients with recurrent oligodendrogliomas. Patients with previously irradiated oligodendrogliomas, either pure or mixed, that were contrast enhancing, measurable, and behaving aggressively at recurrence were eligible for this study. Only complete responders or major partial responders (75% reduction in tumor size) to induction chemotherapy - either intensive-dose procarbazine, lomustine, and vincristine or cisplatin plus etoposide - could receive high-dose thiotepa (300 mg/m2/day for 3 days) followed by hematopoietic reconstitution using either bone marrow or peripheral blood stem cells. Thirty-eight patients began induction chemotherapy and 20 (10 men, 10 women; median age 46 years; median Karnofsky score 80) received high-dose thiotepa. For the high-dose group, the median event-free, progression-free, and overall survival times from recurrence were 17, 20, and 49 months, respectively. Tumor control in excess of 2 years was observed in 6 patients (30%). Four patients (20%) are alive and tumor free 27 to 77 months (median, 42 months) from the start of induction therapy; however, fatal treatment-related toxicities also occurred in 4 patients (20%). Three patients died as a result of a progressive encephalopathy which, in 2 instances, was accompanied by a wasting syndrome; 1 patient died as a consequence of an intracerebral (intratumoral) hemorrhage. Fatal toxicities occurred in patients with pretreatment Karnofsky scores of 60 or 70. High-dose thiotepa to consolidate response was a disappointing treatment strategy for patients with recurrent aggressive oligodendroglial neoplasms, although several patients had durable responses. Moreover, as prescribed, high-dose thiotepa had significant toxic effects in previously irradiated patients, especially those with poorer performance status.

UR - http://www.scopus.com/inward/record.url?scp=0034173311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034173311&partnerID=8YFLogxK

M3 - Article

C2 - 11303620

AN - SCOPUS:0034173311

VL - 2

SP - 114

EP - 119

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 2

ER -